A year after stopping: what the trials found at the far end
The physiology of regain was described a decade before these drugs, and it explains the trajectory without invoking anything specific to them.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 31 of 68 of this archive, newest first.
The physiology of regain was described a decade before these drugs, and it explains the trajectory without invoking anything specific to them.
An absence of evidence is not evidence of harm. It is also not a licence.
A compendial sterility test takes fourteen days of incubation and consumes the containers tested. That timescale is incompatible with the business model that made…
Follow the resin, not the catalogue.
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
A proper account of an operation that existed, and of what closing it cost.
A manufacturer’s certificate is a self-declaration. An accredited laboratory’s report is a third-party measurement. The trade prints both under one heading.
Follow the resin, not the catalogue.
The supplier has not disputed the finding. It has not explained the gap either.
A proper account of an operation that existed, and of what closing it cost.
The document is four pages. Three of them are about dates.
A peptide has a monoisotopic mass and an average mass, they differ by several daltons at this molecular size, and a certificate that does not say which it quotes cannot be…
We work the arithmetic out in full, because it is arithmetic and it is short.
Reported from the analysis, not from a warning notice.
Follow the resin, not the catalogue.
The document is four pages. Three of them are about dates.
A proper account of an operation that existed, and of what closing it cost.
What happens to traceability when bulk material is subdivided, repackaged and relabelled two or three times before sale.
The practical difficulty is not knowing the target. It is meeting it on an appetite that has been pharmacologically reduced by half.
Follow the resin, not the catalogue.
The route did not close because of a rule about peptides.
A proper account of an operation that existed, and of what closing it cost.
Dose reduction is not withdrawal, and the trials that tested withdrawal cannot be read as testing it.
Chain of custody, in a regulated setting, begins at sampling. Here it begins when the package arrives.
The evidence base is thin and the document says so, which is to its credit.
The route did not close because of a rule about peptides.
Reported from the sessions, and from the two hours afterwards.
The report states the gradient, the wavelength and the integration threshold, which is more than most.
Roughly four to seven per cent of trial participants discontinued for adverse events, mostly gastrointestinal, mostly during escalation. That is the empirical size of the…
A body-composition report gives four decimal places and no confidence interval. That is the whole difficulty in one sentence.